



# nivolumab concentrate for solution for infusion (Opdivo®)

Bristol Myers Squibb Pharmaceuticals Limited

05 September 2025

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation **nivolumab (Opdivo®)** is not recommended for use within NHSScotland.

**Indication under review:** in combination with platinum-based chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgical resection, for the treatment of adults with resectable (tumours  $\geq 4$  cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

## Advice context:

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

Chair

Scottish Medicines Consortium